Related Experiment Videos
Abnormalities of the FHIT transcripts in osteosarcoma and Ewing sarcoma
S Hinohara1, N Satake, K Sekine
1Second Clinical Department, Saitama Cancer Center Hospital.
Japanese Journal of Cancer Research : Gann
|November 18, 1998
Summary
The fragile histidine triad (FHIT) gene shows abnormalities in osteosarcoma and Ewing sarcoma. These FHIT gene alterations, including splicing errors and genomic instability, do not appear to impact patient outcomes or metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The fragile histidine triad (FHIT) gene is a potential tumor suppressor.
- FHIT gene abnormalities are implicated in various cancers.
- Understanding FHIT alterations in bone sarcomas is crucial.
Purpose of the Study:
- To investigate FHIT gene abnormalities in osteosarcoma and Ewing sarcoma.
- To analyze the nature of FHIT aberrant transcripts.
- To correlate FHIT alterations with clinical outcomes.
Main Methods:
- Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect FHIT gene transcripts.
- Sequence analysis of PCR products identified specific abnormalities.
- Clinical data, including metastasis and outcome, were analyzed.
Main Results:
- Abnormal FHIT transcripts were found in 11 osteosarcomas and 3 Ewing sarcomas.
- Detected abnormalities included exon deletions and various fusion events within transcripts.
- FHIT abnormalities were not significantly correlated with lung metastasis or poor clinical outcome.
Conclusions:
- Both aberrant splicing and genomic instability contribute to FHIT transcript abnormalities in bone sarcomas.
- Different FHIT transcripts in the same tumor suggest lack of selective proliferation advantage.
- FHIT gene alterations do not appear to be prognostic markers for osteosarcoma or Ewing sarcoma.